Portfolio Company · Operating Co.

C2S

Healthcare

backed byEurazeo

ExitedHealthcare

C2S

a portfolio company of

Eurazeo

Status on record: Exited

Investment year: 2018

PE Firm Index

Who owns C2S?

C2S is listed as an exited portfolio company of Eurazeo on Eurazeo's own portfolio page. Eurazeo invested in C2S in 2018, per Eurazeo's portfolio page.

Company Snapshot

C2S is a Healthcare company. Its owner on record, Eurazeo, is a buyout firm founded in 2001, headquartered in Paris, France, with €35 billion under management. Eurazeo lists 266 companies in the index, 34 of them in Healthcare.

SectorHealthcare

Parent PE firmEurazeo

Ownership statusExited

WebsiteNot on record

About the owner

Eurazeo

Headquarters: Paris, France
Founded: 2001
AUM: €35 billion
Strategy: Buyout, Growth Equity
Sectors: Consumer Goods, Technology, Healthcare
Companies in the index: 266

Eurazeo is a leading French private equity firm and investment group that manages a diversified portfolio of over 600 companies.

Read the Eurazeo profile

Questions about C2S

Who owns C2S?

C2S is listed as an exited portfolio company of Eurazeo on Eurazeo's own portfolio page. Eurazeo invested in C2S in 2018, per Eurazeo's portfolio page.

What sector is C2S in?

C2S is in Healthcare. Classified from the owner's portfolio label.

Where is Eurazeo headquartered?

Eurazeo is headquartered in Paris, France.

What else does Eurazeo own in Healthcare?

Eurazeo lists 33 other Healthcare companies in the index, including 3P Biopharmaceuticals, Amolyt Pharma, Bioserenity, Cardiologs Technologies and Cranial Technologies.

Sources

Eurazeo
https://www.eurazeo.com/en/investments?page=10

This profile is based on publicly available information and may be incomplete or outdated. PE Firm Index is not affiliated with C2S and does not provide investment advice.

Other portfolio companies of Eurazeo

6 of 265 shown

1Komma5°

Tech-enabled

3P Biopharmaceuticals

See the full Eurazeo portfolio.

Other Healthcare companies held by Eurazeo

3P Biopharmaceuticals Amolyt Pharma Bioserenity Cardiologs Technologies Cranial Technologies DNA Script

Other Healthcare portfolio companies

via Wavemaker 360 Health

3Shape

via EQT Partners

6n Systems

via Marlin Equity Partners

A-S Medication Solutions (ASMS)

via Warburg Pincus

Browse PE-backed companies.

Is this your company?

Claiming is free and reviewed by hand. Correct facts and add your team.

Claim this profile Suggest a correction

Ownership

Parent PE firm

Eurazeo

Paris, France

Status: Exited

Investment year: 2018

For PE-backed companies

DevriX

DevriX runs the websites, integrations and data that bring in revenue, as one accountable engineering and operations team, through acquisitions and exit.

Where DevriX helps

Value creation through the holdRevenue, data, web and AI run as one operating cadence, tied to EBITDA.Add-ons and carve-outsConsolidate or separate platforms and unify reporting after a deal.Exit readinessFind the technology and data issues a buyer's diligence would raise, before it does.

Send DevriX a short brief

A short form on devrix.com. No call to book.

Disclosure: PE Firm Index is maintained by Mario Peshev, who founded and runs DevriX. DevriX listing

Weekly PE M&A and market research, by email

The Growth Shuttle Insider is Mario Peshev's weekly newsletter for PE owners and operators. Each issue carries the week's private equity deals from this index, market data and research, and an essay from Mario.

Free. One email a week. Unsubscribe from any issue. Your address goes to beehiiv, the service that sends the Insider.

Research

The 2027 Digital Value Creation Baseline

1,407 PE-backed companies from 179 sponsors, measured from public sources in October 2026. 15% of service and product companies have the full path from search to CRM.

Read the research

Research by Growth Shuttle and DevriX.